{"id":"W2754251024","doi":"10.1200/jco.2017.35.15_suppl.tps4149","title":"The CCTG PA.7 trial: A randomized phase II study of gemcitabine and nab-paclitaxel vs. gemcitabine, nab-paclitaxel, durvalumab, and tremelimumab as 1<sup>st</sup> line therapy in metastatic pancreatic ductal adenocarcinoma (PDAC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; Baker Hughes (Canada); University of Ottawa; Ottawa Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network; McGill University","funders":"","keywords":"Medicine; Gemcitabine; Durvalumab; Tremelimumab; Internal medicine; Oncology; Paclitaxel; Immunogenicity; Cancer; Immunotherapy; Antigen; Immunology; Nivolumab; Ipilimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001957212,0.001866887,0.003455994,0.0005286106,0.0004904886,0.001420885,0.001247383,0.002101849,0.008233169],"category_scores_gemma":[0.002176329,0.0007001648,0.001800766,0.0006317397,0.001196846,0.001216962,0.0004547856,0.004691756,0.001702376],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00160736,"about_ca_system_score_gemma":0.002264939,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002577038,"about_ca_topic_score_gemma":0.006806477,"domain_scores_codex":[0.9991226,0.0005364956,0.00003188159,0.0001067314,0.00006709531,0.00013523],"domain_scores_gemma":[0.9988558,0.0003059038,0.0002425985,0.0000752407,0.00006484793,0.0004556297],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.978129,0.005432129,0.0008448695,0.0004399767,0.000582347,0.00004935029,0.00003423383,0.000360652,0.001618957,0.0001829584,0.002794,0.009531721],"study_design_scores_gemma":[0.9680047,0.02909423,0.001192587,0.00002427611,0.0002700252,0.0000414056,0.00001517888,0.0004391002,0.0001232222,0.000115352,0.0006685887,0.00001137331],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9714863,0.005823221,0.0006278763,0.002279431,0.001494446,0.007498137,0.003534276,0.0002512107,0.007005294],"genre_scores_gemma":[0.9612013,0.003931279,0.002656361,0.003849062,0.001367039,0.01181625,0.006206608,0.0001228742,0.00884936],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008233169,"threshold_uncertainty_score":0.02754265,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1627107659367999,"score_gpt":0.5054009264514338,"score_spread":0.3426901605146339,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}